NCT00392990View on ClinicalTrials.gov

Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 6, 2007

Primary Completion Date

December 3, 2011

Study Completion Date

May 28, 2013

Conditions
Lymphoma
Interventions
DRUG

Regimen A

Cyclophosphamide (800 mg/m2 IV over 1 hour)+ vincristine (1.5 mg/m2 IV PUSH)+ doxorubicin (40 mg/m2 IV)+ high-dose methotrexate (2,700 mg/m2 IV over 23 hours)+ rituximab (500 mg/m2 IV)(R-CODOX-M) regimen

DRUG

Regimen B

Rituximab (500 mg/m2 IV once)+ Ifosfamide (1500 mg/m2 IV daily over 3 hours)+ Etoposide (60 mg/m2 IV daily over 1 hour), and Cytarabine (2 grams/m2 IV over 3 hours for 4 doses)

Trial Locations (8)

44106

University Hospitals Case Medical Center, Cleveland

60153

Loyola University Medical Center, Maywood

60612

John H. Stroger Cook County Hospital, Chicago

Rush University Medical Center, Chicago

63110

Washington University, St Louis

60611-3013

Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago

60068-1174

Advocate Lutheran General Cancer Care Center, Park Ridge

08901

The Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER

NCT00392990 - Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma | Biotech Hunter | Biotech Hunter